| Bioactivity | Adavivint (SM04690; Lorecivivint) is a potent and selective inhibitor of canonical Wnt signaling, with an EC50 of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 colon cancer cells[1]. | ||||||||||||
| Target | EC50: 19.5 nM (Wnt, SW480 cell) | ||||||||||||
| Invitro | Adavivint (SM04690) is a potent and selective inhibitor of Wnt signaling, with an EC50 of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 colon cancer cells, and shows no effect on SV40 luciferase reporter. Adavivint enhances aggregation of human mesenchymal stem cells (hMSCs) with an EC50 of 10 nM. Adavivint (30 nM) protects chondrocytes from catabolic breakdown in vitro[1]. | ||||||||||||
| In Vivo | Adavivint (0.3 μg) enhances cartilage repair and protection in the rat acute cruciate ligament tear and partial medial meniscectomy osteoarthritis (ACLT + pMMx OA) model[1]. | ||||||||||||
| Name | Adavivint | ||||||||||||
| CAS | 1467093-03-3 | ||||||||||||
| Formula | C29H24FN7O | ||||||||||||
| Molar Mass | 505.55 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Deshmukh V, et al. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2018 Jan;26(1):18-27. |
Adavivint
CAS: 1467093-03-3 F: C29H24FN7O W: 505.55
Adavivint (SM04690; Lorecivivint) is a potent and selective inhibitor of canonical Wnt signaling, with an EC50 of 19.5 n
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.